Dual GIP / GLP-1 receptor agonist
Tirzepatide
Single peptide at GIP and GLP-1 receptors, combining incretin insulinotropism with strong effects on appetite and weight in labelled products.
Primary Mechanism of Action
Clinical / Scientific
Tirzepatide activates both GIP receptors and GLP-1 receptors. GIPR agonism contributes to secretion and adipose/nutrient handling; GLP-1R agonism contributes to suppression, gastric emptying delay, and satiety. Clinical products are labelled for diabetes and weight management at defined doses.
Pathway Targets
GIP receptor
Scientific explanation
Incretin agonism.
GLP-1 receptor
Scientific explanation
Incretin / satiety agonism.
Pathway Convergence
Clinical / Scientific
Target → pathway → downstream effect → biological consequence. This is a mechanistic map, not a treatment claim.
Receptor to physiology
Target to downstream effect: GIP receptor → GLP-1 receptor
Mechanistically Relevant Repurposed & Adjunctive Applications
Type 2 diabetes and obesity (labelled pens)
EstablishedMechanistic rationale
Established dual for labelled indications. Research vials are not automatically the same as a licensed delivery system or dose.
Mechanistic Application Matrix
| Biological Target | Mechanism | Potential Relevance | Evidence Level |
|---|---|---|---|
| GIPR | Agonism | Incretin insulinotropism | Established mechanism |
| GLP-1R | Agonism | Satiety / glucagon / emptying | Established mechanism |
Mechanistic Interaction Considerations
Same incretin class cautions as GLP-1RAs: delayed absorption of oral medicines, GI effects, hypoglycaemia with /sulphonylureas.
In Plain Language
Tirzepatide presses two gut-hormone buttons at once (GIP and GLP-1), which is why it can affect blood sugar and appetite strongly.
Compounds Sharing Pathways
Other library compounds whose structured pathway data overlap this ingredient. Shared pathways are not combination recommendations.
GIP receptor
GLP-1 receptor
Mechanistic information is provided for scientific and educational purposes. Discussion of biological pathways or investigational applications does not establish clinical efficacy or constitute individualized medical advice.